摘要
目的探讨孟鲁司特钠联合复方异丙托溴铵治疗儿童哮喘的疗效及对患儿呼吸功能的影响。方法选取2022年1月至2022年12月本院收治的100例小儿哮喘急性发作患儿作为研究对象,随机分为对照组与观察组,每组50例。对照组单一应用复方异丙托溴铵治疗,观察组在对照组基础上给予孟鲁司特钠治疗,比较两组症状消失时间、临床疗效、治疗前后气道功能[呼气高峰流量(PEF)、第1秒用力呼气容积占用力肺活量比值(FEV_(1)/FVC)、达峰容积比(VPEF/VE)、达峰时间比(TPTEF/TE)]、治疗前后炎症因子[白细胞介素-4(IL-4)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、C反应蛋白(CRP)]水平及不良反应发生情况。结果观察组哮鸣音、咳痰、喘息、湿罗音消失时间均短于对照组(P<0.05);观察组治疗总有效率为100.00%,明显高于对照组的82.00%,差异有统计学意义(P<0.05)。治疗前,两组CRP、IL-4、IL-6、IL-10水平比较差异无统计学意义;治疗后,两组CRP、IL-4、IL-6水平均低于治疗前,IL-10水平高于治疗前,且观察组CRP、IL-4、IL-6水平均低于对照组,IL-10水平高于对照组,差异有统计学意义(P<0.05)。治疗前,两组PEF、FEV_(1)/FVC、VPEF/VE、TPTEF/TE比较差异无统计学意义;治疗后,两组PEF、FEV_(1)/FVC、VPEF/VE、TPTEF/TE均大于治疗前,且观察组大于对照组,差异有统计学意义(P<0.05)。两组治疗期间均无不良反应发生。结论小儿哮喘急性发作时采用复方异丙托溴铵、孟鲁司特钠联合治疗效果显著,促进改善临床症状及气道功能,有效控制炎症因子水平,用药安全性好,应用价值较高。
Objective To investigate the efficacy of montelukast sodium combined with compound ipratropium bromide in the treatment of children with asthma and the effects on respiratory function.Methods 100 children with acute asthma attack treated in our hospital from January 2022 to December 2022 were selected as the research subjects,and they were randomly divided into control group and observation group,with 50 cases in each group.The control group was treated with compound ipratropium bromide alone,and the observation group was treated with montelukast sodium on the basis of the control group,the symptom resolution time,clinical efficacy,airway function(peak expiratory flow rate[PEF],forced expiratory volume in the first second/forced vital capacity[FEV_(1)/FVC],volume to peak tidal expiratory flow as a proportion of exhaled volume[VPEF/VE],time to peak tidal expiratory flow/time to expiratory[TPTEF/TE])before and after treatment,levels of inflammatory factors(interleukin-4[IL-4],interleukin-6[IL-6],interleukin-10[IL-10],C-reactive protein[CRP])before and after treatment and the occurrence of adverse reactions were compared between the two groups.Results The disappearance time of wheezing,coughing,wheezing and wet rales in the observation group were shorter than those in the control group(P<0.05).The total effective rate in the observation group was 100.00%,which was significantly higher than 82.00%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in CRP,IL-4,IL-6 and IL-10 levels between the two groups;after treatment,the levels of CRP,IL-4 and IL-6 of the two groups were lower than those before treatment,and the levels of IL-10 were higher than those before treatment,and the levels of CRP,IL-4 and IL-6 in the observation group were lower than those in the control group,and the level of IL-10 was higher than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant diffe
作者
苏建梅
刘爱玲
孙永明
SU Jianmei;LIU Ailing;SUN Yongming(Department of Pediatrics,Yanggu County People's Hospital,Liaocheng,Shandong,252300,China;Department of Pediatrics,Dongchangfu District Maternal and Child Health Hospital,Liaocheng,Shandong,252000,China)
出处
《当代医学》
2023年第10期65-68,共4页
Contemporary Medicine
关键词
小儿哮喘
急性发作
复方异丙托溴铵
孟鲁司特钠
治疗效果
气道功能
Pediatric asthma
Acute attack
Compound ipratropium bromide
Montelukast sodium
Therapeutic effect
Airway function
